Foghorn Therapeutics Inc. Common Stock (FHTX) Stock
Key stats
- Market cap
- $119.36M
- Price / Earnings ratio
- -1.9x
- EPS (TTM)
- -$4.11
- Volume
- Loading
- 52-week high
- $7.61
- 52-week low
- $1.79
Source: third-party data provider, as of October 24, 2026
Compare with FHTX
Recent news

FHTX Investors with $100,000 in Losses Have Opportunity to Join Foghorn Therapeutics Inc. Fraud Investigation with SBS Law
FHTX Investors with $100,000 in Losses Have Opportunity to Join Foghorn Therapeutics Inc. Fraud Investigation with SBS Law
FHTX

FHTX Stock Extends Sell-Off After Lilly Collaboration Ends — Wedbush Slashes Target By 80%
FHTX Stock Extends Sell-Off After Lilly Collaboration Ends — Wedbush Slashes Target By 80%
FHTX

Foghorn to cut 40% of workforce after scrapping Lilly-partnered cancer drug
Foghorn to cut 40% of workforce after scrapping Lilly-partnered cancer drug
FHTX

Wall Street Analysts Think Foghorn Therapeutics (FHTX) Could Surge 67.01%: Read This Before Placing a Bet
Wall Street Analysts Think Foghorn Therapeutics (FHTX) Could Surge 67.01%: Read This Before Placing a Bet
FHTX
News tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 24.74
- MACD 12/26/9
- -0.60
- EMA 9 of MACD
- -0.70
- MACD histogram
- 0.10
- SMA 50
- $4.16
- Price below SMA 50
- EMA 50
- $3.49
- Price below EMA 50
- SMA 200
- $4.82
- Price below SMA 200
- EMA 200
- $4.54
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of October 22, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Hold
Based on 5 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
No data available
Debt & Balance Sheet
No data available
Revenue to Profit
No data available
Earnings
No data available
Source: third-party data provider
Latest news

FHTX Investors with $100,000 in Losses Have Opportunity to Join Foghorn Therapeutics Inc. Fraud Investigation with SBS Law
FHTX Investors with $100,000 in Losses Have Opportunity to Join Foghorn Therapeutics Inc. Fraud Investigation with SBS Law
FHTX

FHTX Stock Extends Sell-Off After Lilly Collaboration Ends — Wedbush Slashes Target By 80%
FHTX Stock Extends Sell-Off After Lilly Collaboration Ends — Wedbush Slashes Target By 80%
FHTX

Foghorn to cut 40% of workforce after scrapping Lilly-partnered cancer drug
Foghorn to cut 40% of workforce after scrapping Lilly-partnered cancer drug
FHTX

Wall Street Analysts Think Foghorn Therapeutics (FHTX) Could Surge 67.01%: Read This Before Placing a Bet
Wall Street Analysts Think Foghorn Therapeutics (FHTX) Could Surge 67.01%: Read This Before Placing a Bet
FHTX

3 Cancer Stocks to Buy Amid Rapid Advances in Cancer Treatment
3 Cancer Stocks to Buy Amid Rapid Advances in Cancer Treatment
FHTX
News tone: automated (AI) classification of the article's content, not a price prediction.
About Foghorn Therapeutics Inc. Common Stock
Foghorn Therapeutics Inc is a clinical stage, precision therapeutics biotechnology company focused on pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression through selectively targeting the chromatin regulatory system. Its proprietary platform is designed to provide an integrated, mechanistic understanding of interactions within the chromatin regulatory system, supporting the identification and validation of potential therapeutic targets. The company's flagship program is FHD-909.
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of October 24, 2026
Technical indicators
- RSI 14
- 24.74
- MACD 12/26/9
- -0.60
- EMA 9 of MACD
- -0.70
- MACD histogram
- 0.10
- SMA 50
- $4.16
- Price below SMA 50
- EMA 50
- $3.49
- Price below EMA 50
- SMA 200
- $4.82
- Price below SMA 200
- EMA 200
- $4.54
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of October 22, 2026. Technical data, not a recommendation.
Analyst views
5 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $2.00
- Average
- $4.00
- High
- $5.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | +1.4 | -31.2 |



